Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dapagliflozin vs Gliclazide MR on Glycemic Variability in T2DM
NCT02925559Phase 4Completed
- Sponsor
- Centro de Diabetes Curitiba
- Start
- Oct 2016
- Primary completion
- Feb 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of dapagliflozin in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Centro de Diabetes Curitiba. Primary endpoint: Mean Amplitude of Glycemic Excursion at 12 weeks. Started Oct 2016; status: completed.
02
Drugs
dapagliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT02925559.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02925559.